Table 1.
Clinical characteristics of study population.
| Variable | Timepoint | Viral success | Viral failure | Viral failureLow | Viral failureHigh |
|---|---|---|---|---|---|
| No. of patients (n = 17) | 6 | 11 | 5 | 6 | |
| Age (years)a | 8 (4–14) | 7 (2–17) | 9 (3–17) | 7 (2–16) | |
| CD4 T cells (/µl)b | Baseline | 225 (156–425) | 302 (93–480) | 256 (181–540) | 306 (48–503) |
| 24 Weeks | 562 (446–1218) | 495 (454–698) | 486 (399–751) | 509 (462–738) | |
| CD4 cell (%)b | Baseline | 12 (8–32) | 18 (8–22) | 18 (15–24) | 13 (8–22) |
| 24 Weeks | 28 (24–36) | 24 (20–28) | 27 (25–30) | 22 (16–24) | |
| Plasma viral RNA (log10 copies/ml)b | Baseline | 5.0 (4.0–5.4) | 5.1 (4.2–5.7) | 4.3 (4.0–4.7) | 5.5 (5.1–5.9) |
| 24 Weeks | 2.6 (2.6–2.6) | 4.5 (3.7–5.3) | 3.6 (3.4–4.4) | 4.9 (4.5–5.4) | |
| CD4:CD8 ratiob | Baseline | 0.20 (0.12–1.30) | 0.41 (0.24–0.66) | 0.41 (0.37–0.56) | 0.35 (0.11–0.71) |
| 24 Weeks | 0.64 (0.44–2.12) | 0.89 (0.42–1.06) | 1.00 (0.79–1.12) | 0.54 (0.39–0.90) |
a
Median value (range).
b
Median value (25th–75th interquartile range).